BackVentriPoint Diagnostics Overview
VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Return on Equity

Valuation check: VPTDF's ROE is 60.47%, above the sector sector average of 11.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

60.47%

Return on Equity

60.47%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

VentriPoint Diagnostics (VPTDF) FAQ

VentriPoint Diagnostics (VPTDF) currently reports a ROE of 60.47%. That is above the sector sector average of 11.3%. Use the charts on this page to explore VentriPoint Diagnostics's ROE history and peer comparisons.

VentriPoint Diagnostics's ROE of 60.47% is higher than the its sector sector average of 11.3%. That is roughly 435.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but VentriPoint Diagnostics's current 60.47% should be judged against industry norms (sector average: 11.3%) and against VPTDF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 60.47%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.3%. From there, open related valuation or income-statement pages for VentriPoint Diagnostics, and consider following VPTDF for alerts when major investors trade the stock.